SEROTONİNİN MEME KANSERİNDEKİ ROLÜ
Abstract views: 3
/ 
PDF downloads: 7
Keywords:
Serotonin, 5-HT, 5-HT Reseptörleri, Kanser, Kanser OluşumuAbstract
Serotonin (5-hidroksitriptamin, 5-HT), esansiyel amino asit triptofandan üretilen biyojenik bir
monoamindir. Serotoninin merkezi sinir sisteminde bir nörotransmiter ve gastrointestinal sistemde bir
motilite aracısı olarak rolü iyi tanımlanmıştır ve çeşitli kanserlerde (gliomalar, karsinoidler ve karsinomlar)
tümör oluşumundaki işlevi araştırılmaktadır. Birçok çalışma, serotoninin kanser hücresi çoğalması, istilası,
yayılması ve tümör anjiyogenezi üzerinde potansiyel uyarıcı etkisini göstermiştir. Altta yatan mekanizma
karmaşık olmasına rağmen tümördeki serotonin düzeylerinin ve bunun spesifik reseptör alt tipleri ile
etkileşiminin hastalığın ilerlemesi ile ilişkili olduğu öne sürülmektedir. Çeşitli çalışmalardan elde edilen
sonuçlar, tümörlerdeki serotonin düzeylerinin kanserin ilerlemesinde önemli bir rol oynadığını
göstermektedir. Serotonin reseptörleri, seçici serotonin taşıyıcıları ve serotonin sentez yolu, tedavi
seçeneklerinin sınırlı olduğu birçok kanserin tedavisinde potansiyel kemoterapötik hedeflerdir. Birçok
çalışma, serotoninin kanser hücresi çoğalması, istilası, yayılması ve tümör anjiyogenezi üzerinde potansiyel
uyarıcı etkisini göstermiştir. Altta yatan mekanizma karmaşık olmasına rağmen tümördeki serotonin
düzeylerinin ve bunun spesifik reseptör alt tipleri ile etkileşiminin hastalığın ilerlemesi ile ilişkili olduğu
öne sürülmektedir. Bu derleme makalesi, serotoninin ve meme kanser patogenezindeki rolünü
açıklamaktadır.
Downloads
References
Agarwal, A., Agarwal, M., Garg, K. et al (2016). Metabolic syndrome and central obesity in depression: a cross-sectional study. Indian J Psychiatry, 58, 281-286.
Bakshi, A., Tadi, P. Biochemistry, Serotonin. [Updated 2022 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK560856/
Bambace, N.M., Holmes, C.E. (2011). The platelet contribution to cancer progression. J Thromb Haemost, 9(2), 237-49
Bamalan, O.A., Moore, M.J., Al Khalili, Y. (2023). Fizyoloji, Serotonin. StatPearls. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK545168/
Basilion, J. (2001). Breast imaging technology: Current and future technologies in breast cancer imaging. Breast Cancer Res., 3, 13-14.
Berger M, Gray JA, Roth BL. (2009). The expanded biology of serotonin. Annu Rev Med., 60, 355-66.
Brandes, L.J., Arron, R.J., Bogdanovic, R.P., Tong, J., Zaborniak, C.L., Hogg, G.R., Warrington, R.C., Fang, W., Labella, F.S. (1992). Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res., 52, 3796-3800.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68, 394-424.
Clevenger, C.V., Rui, H. (2022). Breast cancer and prolactin—New mechanisms and models. Endocrinology, 163, bqac122.
David, D.J., Gardier, A.M. (2016). The pharmacological basis of the serotonin system: Application to antidepressant response. Encephale, 42(3), 255-63.
Dick, J.E. (2008). Stem cell concepts renew cancer research. Blood, 112, 4793-4807.
Dizeyi, N., Bjartell, A., Hedlund, P, Taskén, K.A., Gadaleanu, V., Abrahamsson, PA. (2005). Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines. Eur Urol., 47(6), 895-900.
Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K, Abrahamsson PA. (2011). Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. Urol Oncol, 29(4), 436-45.
Duncan, W., Kerr, G.R. (1976). Meme kanserinin tedavi edilebilirliği. br. Med. J., 2, 781-783.
Eom, C.-S., Park, S.M., Cho, K.-H. (2012). Use of antidepressants and the risk of breast cancer: A meta-analysis. Breast Cancer Res. Treat., 136, 635-645.
Iranmakani, S., Mortezazadeh, T., Sajadian, F., Ghaziani, M.F., Ghafari, A., Khezerloo, D., Musa, A.E. (2020). Review of various methods in breast imaging: Technical aspects and clinical results. Sweetcorn. J. Radiol. Core Med., 51, 57.
Gaspar, P., Lillesaar, C. (2012). Probing the diversity of serotonin neurons. Philos. Trans. R. Soc. B Biol. Sci., 367, 2382-2394.
George, J., Siegel (2006). Basic Neurochemistry Molecular, Cellular And Medıcal Aspects, 7th Ed, Elsevier Academic Press Burlington, MA , USA, 227-248.
Gupta, R. (2014). Serotonergic Receptors. In: Pain Management. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55061-4_14
Gutschner, T., Diederichs, S. (2012). The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol., 9(6), 703-19.
Gwynne, W.D., Shakeel, M.S., Girgis-Gabardo, A., Hassell, J.A. (2021). The Role of Serotonin in Breast Cancer Stem Cells. Molecules, 26(11), 3171.
Gwynne, W.D., Hallett, R.M., Girgis-Gabardo, A., Bojovic, B., Dvorkin-Gheva, A., Aarts, C., Dias, K., Bane, A., Hassell, J.A. (2017). Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts. Oncotarget, 8, 32101-32116.
Harvey, P.W., Everett, D.J., Springall, C.J. (2008). Adverse effects of prolactin in rodents and humans: breast and prostate cancer. J Psychopharmacol, 22, 20-27.
Horseman, N.D., Collier, R.J. (2014). Serotonin: a local regulator in the mammary gland epithelium. Annu Rev Anim Biosci, 2, 353-74.
Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin) Pharmacol. Rev., 46, 157-203
Johannessen, C.M., Johnson, L.A., Piccioni, F., Townes, A., Frederick, D.T., Donahue, M.K., Narayan, R., Flaherty, K.T., Wargo, J.A., Root, D.E., et al. (2013). A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nat. Cell Biol., 504, 138-142.
Karmakar, S., Lal, G. (2021). Role of serotonin receptor signaling in cancer cells and anti-tumor immunity. Theranostics, 11(11), 5296-12.
Kitson, S.L. (2007). 5-hydroxytryptamine (5-HT) receptor ligands. Curr Pharm Des., 13(25), 2621-37.
Konermann, S., Brigham, M., Trevino, A.E., Joung, J., Abudayyeh, O.O., Barcena, C., Hsu, P.D., Habib, N., Gootenberg, J., Nishimasu, H., et al. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nat. Cell Biol., 517, 583-588.
Leboyer, M., Philippe, A., Bouvard, M., Guilloud-Bataille, M., Bondoux. D., Tabuteau, F., Feingold, J., Mouren-Simeoni, M.C., Launay, J.M. (1999). Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry, 45(2), 158-63.
Marin, P., Becamel, C., Dumuis, A., Bockaert, J. (2012). 5-HT receptor-associated protein networks: New targets for drug discovery in psychiatric disorders? Curr. Drug Targets, 13, 28-52
Medrihan, L., Sagi, Y., Inde, Z .et al. (2017). Initiation of behavioral response to antidepressants by cholecystokinin neurons of the dentate gyrus. Neuron, 95, 564-576.e4
Mohammad-Zadeh, L.F., Moses, L., Gwaltney-Brant, S.M. (2008). Serotonin: A review. J. Vet. Pharmacol. Ther., 31, 187-199.
Olfati, Z., Rigi, G., Vaseghi, H., Zamanzadeh, Z., Sohrabi, M., Hejazi, S.H. (2020). Evaluation of serotonin receptors (5HTR2A and 5HTR3A) mRNA expression changes in tumor of breast cancer patients. Med. J. Islam Repub. Iran, 34, 99.
Pai, V.P., Marshall, A.M., Hernandez, L.L., Buckley, A.R., Horseman, N.D. (2009). Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res., 11, R81.
Papageorgiou, A., Denef, C. (2007). Stimulation of growth hormone release by 5-hydroxytryptamine (5-HT) in cultured rat anterior pituitary cell aggregates: evidence for mediation by 5-HT2B, 5-HT7, 5-HT1B, and ketanserin-sensitive receptors. Endocrinology, 148, 4509-22.
Peters, M.A., Walenkamp, A.M., Kema, I.P., Meijer, C., de Vries, E.G., Oosting, S.F. (2014). Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. Drug Resist Updat., 17(4-6), 96-104.
Phi Van, D.K., Mühlbauer, E., Phi-Van, L. (2015). Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells. Biochim Biophys Acta, 1849(8), 909-18.
Radin, D.P., Patel, P. (2017). A current perspective on the oncopreventive and oncolytic properties of selective serotonin reuptake inhibitors. Biomed Pharmacother, 87, 636-639.
Rosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D.C., Moser, A.R., MacLeod, C.L., Shyamala, G., Gillgrass, A.E., Cardiff, R.D. (2002). Pathway Pathology: Histological Differences Between ErbB/Ras and Wnt Pathway Transgenic Mammary Tumors. Am. J. Pathol, 161, 1087-1097.
Roth, B.L. (2006). The Serotonin Receptors: From Molecular Pharmacology to Human Thereapeutics. Springer Science & Business Media; Berlin, Germany, 537-565.
Sarrouilhe, D., Mesnil, M. (2019). Serotonin and human cancer: A critical view. Biochimie, 161, 46-50.
Sarrouilhe, D., Clarhaut, J., Defamie, N., Mesnil, M. (2015). Serotonin and cancer: what is the link? Curr Mol Med, 15, 62-77.
Seiler, A., Chen, M.A., Brown, R.L., Fagundes, C.P. (2018) Obesity, dietary factors, nutrition, and breast cancer risk. Curr Breast Cancer Rep, 10, 14-27.
Siegel, R.L., Miller KD, Fuchs HE, Jemal A. Kanser İstatistikleri, 2021. CA A Cancer J. Clin., 71, 7-33.
Sonier, B., Arseneault, M., Lavigne, C., Ouellette, R.J., Vaillancourt, C. (2006). The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun, 343(4), 1053-9.
Sola-Penna, M., Paixão, L.P., Branco, J.R., Ochioni, AC., Albanese, J.M., Mundim, D.M., et al. (2020). Jan; Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively. Br J Cancer 122, 194-08.
Schneider, M.A., Heeb, L., Beffinger, M.M., Pantelyushin. S., Linecker, M., Roth, L., Lehmann, K., Ungethüm, U., Kobold, S., Graf, R., Van Den Broek, M., Vom Berg, J., Gupta, A., Clavien, PA. (2021). Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med., 13(611), eabc8188.
Smith, C., Smith, M., Cunningham, R., Davis, S. (2020). Recent Advances in Antiemetics: New Formulations of 5-HT3 Receptor Antagonists in Adults. Cancer Nurs., 43(4), E217-E228.
Tworoger, S.S., Eliassen, A.H., Zhang, X. et al. (2013). A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Can Res, 73, 4810-4819.
Quintero-Villegas, A., Valdés-Ferrer, S.I. (2019). Role of 5-HT(7) receptors in the immune system in health and disease. Mol Med., 26, 019-0126.,
Walther, D.J., Peter, J.U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink H. et al. (2003). Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science, 299, 1078197.
Rapport, M.M., Green, A.A., Page, I.H. (1948). Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem, 176, 1243-51.
Wright, C.E., Angus, J.A. (1989). 5-carboxamidotryptamine elicits 5-HT2 and 5-HT3 receptor-mediated cardiovascular responses in the conscious rabbit: Evidence for 5-HT release from platelets. J. Cardiovasc. Pharmacol, 13, 557-564.
Youn, B.S., Sen, A., Kallos, M.S., Behie, L.A., Girgis-Gabardo, A., Kurpios, N., Barcelon, M., Hassell, J.A. (2008). Large-Scale Expansion of Mammary Epithelial Stem Cell Aggregates in Suspension Bioreactors. Biotechnol. Prog., 21, 984-993.
Zamani, A., Qu, Z. (2012). Serotonin activates angiogenic phosphorylation signaling in human endothelial cells. FEBS Lett, 586, 2360-5.
Zhang, X.-H., Xiao, C. (2018). Diagnostic Value of Nineteen Different Imaging Methods in Breast Cancer Patients: A Network Meta-Analysis. Cell. Fizyol. Biochemistry, 46, 2041-2055.
Zhou, T., Duan, J., Wang, Y., Chen, X., Zhou, G., Wang, R., Fu, L., Xu, F. (2012). Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumor Biol., 33, 1299-1306.
